[A24-10] Migalastat (Fabry disease) – Addendum to Commission A23-88
Last updated 15.02.2024
Project no.:
A24-10
Commission:
Commission awarded on 16.01.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://dx.doi.org/10.60584/A24-10_en
| Project no. | Title | Status |
|---|---|---|
| A23-88 | Migalastat (Fabry disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.